Nikko Asset Management Americas Inc. acquired a new position in shares of Arcturus Therapeutics Ltd (NASDAQ:ARCT) in the first quarter, Holdings Channel reports. The institutional investor acquired 64,099 shares of the biotechnology company’s stock, valued at approximately $438,000.
Separately, JPMorgan Chase & Co. increased its holdings in Arcturus Therapeutics by 91.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock worth $148,000 after purchasing an additional 8,008 shares in the last quarter. 10.86% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have commented on ARCT. HC Wainwright began coverage on Arcturus Therapeutics in a report on Friday, April 5th. They set a “buy” rating and a $15.00 price objective for the company. Zacks Investment Research raised Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price objective for the company in a report on Tuesday, April 16th. ValuEngine raised Arcturus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 30th. Chardan Capital reissued a “buy” rating and set a $18.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday, March 19th. Finally, Roth Capital reissued a “buy” rating on shares of Arcturus Therapeutics in a report on Wednesday, February 20th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $13.83.
Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Monday, March 18th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.41. The business had revenue of $7.58 million during the quarter, compared to the consensus estimate of $3.59 million. On average, research analysts expect that Arcturus Therapeutics Ltd will post -2.11 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://weekherald.com/2019/05/03/nikko-asset-management-americas-inc-takes-position-in-arcturus-therapeutics-ltd-arct.html.
Arcturus Therapeutics Profile
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
Further Reading: How are dividend achievers different from dividend aristocrats?
Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Ltd (NASDAQ:ARCT).
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.